{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:52:34Z","timestamp":1786485154555,"version":"build-2736575974"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T00:00:00Z","timestamp":1502150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40265-017-0793-2","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T14:31:21Z","timestamp":1502202681000},"page":"1531-1547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Current and Emerging Options for the Management of Inherited von Willebrand Disease"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1069-8097","authenticated-orcid":false,"given":"Jessica M.","family":"Heijdra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-2995","authenticated-orcid":false,"given":"Marjon H.","family":"Cnossen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-1371","authenticated-orcid":false,"given":"Frank W. G.","family":"Leebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,8]]},"reference":[{"issue":"2","key":"793_CR1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","volume":"14","author":"WL Nichols","year":"2008","unstructured":"Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171\u2013232.","journal-title":"Haemophilia."},{"issue":"2","key":"793_CR2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","volume":"69","author":"F Rodeghiero","year":"1987","unstructured":"Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand\u2019s disease. Blood. 1987;69(2):454\u20139.","journal-title":"Blood."},{"issue":"5584","key":"793_CR3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1126\/science.107355","volume":"297","author":"EG Huizinga","year":"2002","unstructured":"Huizinga EG, Tsuji S, Romijn RA, Schiphorst ME, de Groot PG, Sixma JJ, et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science. 2002;297(5584):1176\u20139.","journal-title":"Science."},{"issue":"3","key":"793_CR4","first-page":"265","volume":"14","author":"JJ Sixma","year":"1977","unstructured":"Sixma JJ, Wester J. The hemostatic plug. Semin Hematol. 1977;14(3):265\u201399.","journal-title":"Semin Hematol."},{"issue":"21","key":"793_CR5","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","volume":"375","author":"FW Leebeek","year":"2016","unstructured":"Leebeek FW, Eikenboom JC. Von Willebrand\u2019s disease. N Engl J Med. 2016;375(21):2067\u201380.","journal-title":"N Engl J Med."},{"key":"793_CR6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.cb.06.110190.001245","volume":"6","author":"DD Wagner","year":"1990","unstructured":"Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217\u201346.","journal-title":"Annu Rev Cell Biol."},{"issue":"4","key":"793_CR7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","volume":"1","author":"JE Kaufmann","year":"2003","unstructured":"Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost. 2003;1(4):682\u20139.","journal-title":"J Thromb Haemost."},{"issue":"12","key":"793_CR8","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1182\/blood-2002-05-1401","volume":"100","author":"JF Dong","year":"2002","unstructured":"Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002;100(12):4033\u20139.","journal-title":"Blood."},{"issue":"10","key":"793_CR9","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","volume":"4","author":"JE Sadler","year":"2006","unstructured":"Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103\u201314.","journal-title":"J Thromb Haemost."},{"issue":"10","key":"793_CR10","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/j.1538-7836.2005.01571.x","volume":"3","author":"CJ Schooten","year":"2005","unstructured":"Schooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, Mourik JA, et al. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost. 2005;3(10):2228\u201337.","journal-title":"J Thromb Haemost."},{"issue":"8","key":"793_CR11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jth.13368","volume":"14","author":"J Boender","year":"2016","unstructured":"Boender J, Kruip MJ, Leebeek FW. A diagnostic approach to mild bleeding disorders. J Thromb Haemost. 2016;14(8):1507\u201316.","journal-title":"J Thromb Haemost."},{"issue":"9","key":"793_CR12","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","volume":"8","author":"F Rodeghiero","year":"2010","unstructured":"Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al. ISTH\/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8(9):2063\u20135.","journal-title":"J Thromb Haemost."},{"issue":"6","key":"793_CR13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/hae.12503","volume":"20","author":"M Elbatarny","year":"2014","unstructured":"Elbatarny M, Mollah S, Grabell J, Bae S, Deforest M, Tuttle A, et al. Normal range of bleeding scores for the ISTH-BAT: adult and pediatric data from the merging project. Haemophilia. 2014;20(6):831\u20135.","journal-title":"Haemophilia."},{"issue":"5","key":"793_CR14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1055\/s-0031-1281032","volume":"37","author":"EM Wee De","year":"2011","unstructured":"De Wee EM, Leebeek FWG, Eikenboom JCJ. Diagnosis and management of von Willebrand Disease in the Netherlands. Semin Thromb Hemost. 2011;37(5):480\u20137.","journal-title":"Semin Thromb Hemost."},{"issue":"4","key":"793_CR15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/hae.12635","volume":"21","author":"SCM Stoof","year":"2015","unstructured":"Stoof SCM, van Steenbergen HW, Zwagemaker A, Sanders YV, Cannegieter SC, Duvekot JJ, et al. Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia. 2015;21(4):505\u201312.","journal-title":"Haemophilia."},{"issue":"3","key":"793_CR16","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1111\/hae.12670","volume":"21","author":"KPM Galen van","year":"2015","unstructured":"van Galen KPM, Sanders YV, Vojinovic U, Eikenboom J, Cnossen MH, Schutgens REG, et al. Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. Haemophilia. 2015;21(3):e185\u201392.","journal-title":"Haemophilia."},{"issue":"11","key":"793_CR17","doi-asserted-by":"crossref","first-page":"e3038","DOI":"10.1097\/MD.0000000000003038","volume":"95","author":"A Veyradier","year":"2016","unstructured":"Veyradier A, Boisseau P, Fressinaud E, Caron C, Ternisien C, Giraud M, et al. A laboratory phenotype\/genotype correlation of 1167 French patients from 670 families with von Willebrand disease: a new epidemiologic picture. Medicine. 2016;95(11):e3038.","journal-title":"Medicine."},{"issue":"5","key":"793_CR18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0031-1281031","volume":"37","author":"DJ Hampshire","year":"2011","unstructured":"Hampshire DJ, Goodeve AC. The international society on thrombosis and haematosis von Willebrand disease database: an update. Semin Thromb Hemost. 2011;37(5):470\u20139.","journal-title":"Semin Thromb Hemost."},{"issue":"3","key":"793_CR19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/jth.12130","volume":"11","author":"M Bowman","year":"2013","unstructured":"Bowman M, Tuttle A, Notley C, Brown C, Tinlin S, Deforest M, et al. The genetics of Canadian type 3 von Willebrand disease: further evidence for co-dominant inheritance of mutant alleles. J Thromb Haemost. 2013;11(3):512\u201320.","journal-title":"J Thromb Haemost."},{"issue":"1","key":"793_CR20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2006-05-020784","volume":"109","author":"A Goodeve","year":"2007","unstructured":"Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood. 2007;109(1):112\u201321.","journal-title":"Blood."},{"issue":"1","key":"793_CR21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1182\/blood-2006-05-021105.","volume":"109","author":"PD James","year":"2007","unstructured":"James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, et al. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood. 2007;109(1):145\u201354.","journal-title":"Blood."},{"issue":"3","key":"793_CR22","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2010.03.003","volume":"24","author":"AC Goodeve","year":"2010","unstructured":"Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev. 2010;24(3):123\u201334.","journal-title":"Blood Rev."},{"issue":"9","key":"793_CR23","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1111\/j.1538-7836.2010.03957.x","volume":"8","author":"G Castaman","year":"2010","unstructured":"Castaman G, Tosetto A, Eikenboom JC, Rodeghiero F. Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. J Thromb Haemost. 2010;8(9):2078\u201380.","journal-title":"J Thromb Haemost."},{"issue":"7","key":"793_CR24","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","volume":"111","author":"L Gallinaro","year":"2008","unstructured":"Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008;111(7):3540\u20135.","journal-title":"Blood."},{"issue":"26","key":"793_CR25","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1182\/blood-2012-10-457507","volume":"121","author":"N Rydz","year":"2013","unstructured":"Rydz N, Swystun LL, Notley C, Paterson AD, Riches JJ, Sponagle K, et al. The C-type lectin receptor CLEC4M binds, internalizes, and clears von Willebrand factor and contributes to the variation in plasma von Willebrand factor levels. Blood. 2013;121(26):5228\u201337.","journal-title":"Blood."},{"issue":"9","key":"793_CR26","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1182\/blood-2011-08-373605","volume":"119","author":"G Rastegarlari","year":"2012","unstructured":"Rastegarlari G, Pegon JN, Casari C, Odouard S, Navarrete AM, Saint-Lu N, et al. Macrophage LRP1 contributes to the clearance of von Willebrand factor. Blood. 2012;119(9):2126\u201334.","journal-title":"Blood."},{"issue":"12","key":"793_CR27","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/CIRCULATIONAHA.109.869156","volume":"121","author":"NL Smith","year":"2010","unstructured":"Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, Soranzo N, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation. 2010;121(12):1382\u201392.","journal-title":"Circulation."},{"issue":"7","key":"793_CR28","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ejhg.2015.222","volume":"24","author":"J Loon van","year":"2016","unstructured":"van Loon J, Dehghan A, Weihong T, Trompet S, McArdle WL, Asselbergs FF, et al. Genome-wide association studies identify genetic loci for low von Willebrand factor levels. Eur J Hum Genet. 2016;24(7):1035\u201340.","journal-title":"Eur J Hum Genet."},{"issue":"2","key":"793_CR29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1073\/pnas.1219885110","volume":"110","author":"KC Desch","year":"2013","unstructured":"Desch KC, Ozel AB, Siemieniak D, Kalish Y, Shavit JA, Thornburg CD, et al. Linkage analysis identifies a locus for plasma von Willebrand factor undetected by genome-wide association. Proc Natl Acad Sci USA. 2013;110(2):588\u201393.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"793_CR30","doi-asserted-by":"crossref","first-page":"e91687","DOI":"10.1371\/journal.pone.0091687","volume":"9","author":"JE Loon van","year":"2014","unstructured":"van Loon JE, Sonneveld MA, Praet SF, de Maat MP, Leebeek FW. Performance related factors are the main determinants of the von Willebrand factor response to exhaustive physical exercise. PLoS One. 2014;9(3):e91687.","journal-title":"PLoS One."},{"issue":"14","key":"793_CR31","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","volume":"350","author":"J Danesh","year":"2004","unstructured":"Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387\u201397.","journal-title":"N Engl J Med."},{"issue":"2","key":"793_CR32","first-page":"107","volume":"7","author":"AD Blann","year":"1993","unstructured":"Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens. 1993;7(2):107\u201311.","journal-title":"J Hum Hypertens."},{"issue":"1","key":"793_CR33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1160\/TH11-07-0481","volume":"107","author":"HM Knol","year":"2012","unstructured":"Knol HM, Kemperman RF, Kluin-Nelemans HC, Mulder AB, Meijer K. Haemostatic variables during normal menstrual cycle. A systematic review. Thromb Haemost. 2012;107(1):22\u20139.","journal-title":"Thromb Haemost."},{"issue":"7","key":"793_CR34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jth.12586","volume":"12","author":"YV Sanders","year":"2014","unstructured":"Sanders YV, Giezenaar MA, Laros-van Gorkom BAP, Meijer K, van der Bom JG, Cnossen MH, et al. Von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost. 2014;12(7):1066\u201375.","journal-title":"J Thromb Haemost."},{"issue":"4","key":"793_CR35","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1538-7836.2005.01242.x","volume":"3","author":"UM Vischer","year":"2005","unstructured":"Vischer UM, Herrmann FR, Peyrard T, Nzietchueng R, Benetos A. Plasma von Willebrand factor and arterial aging. J Thromb Haemost. 2005;3(4):794\u20135.","journal-title":"J Thromb Haemost."},{"issue":"8","key":"793_CR36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/MBC.0000000000000158","volume":"25","author":"DA Siew","year":"2014","unstructured":"Siew DA, Mangel J, Laudenbach L, Schembri S, Minuk L. Desmopressin responsiveness at a capped dose of 15\u03bcg in type 1 von Willebrand disease and mild hemophilia A. Blood Coagul Fibrinolysis. 2014;25(8):820\u20133.","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"1","key":"793_CR37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2516.2011.02572.x","volume":"18","author":"ME Seary","year":"2012","unstructured":"Seary ME, Feldman D, Carcao MD. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII: C level and with haemophilic genotype. Haemophilia. 2012;18(1):50\u20135.","journal-title":"Haemophilia."},{"issue":"2","key":"793_CR38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2265.1993.tb00990.x","volume":"38","author":"A Fjellestad-Paulsen","year":"1993","unstructured":"Fjellestad-Paulsen A, Hoglund P, Lundin S, Paulsen O. Pharmacokinetics of 1-deamino-8-d-arginine vasopressin after various routes of administration in healthy volunteers. Clin Endocrinol (Oxf). 1993;38(2):177\u201382.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"7","key":"793_CR39","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","volume":"111","author":"G Castaman","year":"2008","unstructured":"Castaman G, Lethagen S, Federici AB, Tosetto A, Goodeve A, Budde U, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood. 2008;111(7):3531\u20139.","journal-title":"Blood."},{"issue":"6","key":"793_CR40","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1182\/blood.V74.6.1997.1997","volume":"74","author":"F Rodeghiero","year":"1989","unstructured":"Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusion in patients with von Willebrand\u2019s disease and hemophilia A. Blood. 1989;74(6):1997\u20132000.","journal-title":"Blood."},{"issue":"1","key":"793_CR41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2141.1992.tb04598.x","volume":"82","author":"PM Mannucci","year":"1992","unstructured":"Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol. 1992;82(1):87\u201393.","journal-title":"Br J Haematol."},{"issue":"11","key":"793_CR42","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/00043426-200311000-00010","volume":"25","author":"S Revel-Vilk","year":"2003","unstructured":"Revel-Vilk S, Schmugge M, Carcao MD, Blanchette P, Rand ML, Blanchette VS. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J Pediatr Hematol Oncol. 2003;25(11):874\u20139.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"6","key":"793_CR43","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","volume":"103","author":"AB Federici","year":"2004","unstructured":"Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, Goudemand J, et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood. 2004;103(6):2032\u20138.","journal-title":"Blood."},{"issue":"4","key":"793_CR44","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1160\/TH10-11-0697","volume":"105","author":"G Castaman","year":"2011","unstructured":"Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von willebrand disease and increased von Willebrand factor clearance. Thromb Haemost. 2011;105(4):647\u201354.","journal-title":"Thromb Haemost."},{"issue":"1","key":"793_CR45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-0038-1647265","volume":"64","author":"A Casonato","year":"1990","unstructured":"Casonato A, Sartori MT, De Marco L, Girolami A. 1-Desamino-8-d-arginine vasopressin (DDAVP) infusion in type IIB von Willebrand\u2019s disease: Shortening of bleeding time and induction of a variable pseudothrombocytopenia. Thromb Haemost. 1990;64(1):117\u201320.","journal-title":"Thromb Haemost."},{"issue":"1","key":"793_CR46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/hae.12732","volume":"22","author":"SCM Stoof","year":"2016","unstructured":"Stoof SCM, Cnossen MH, de Maat MPM, Leebeek FWG, Kruip MJHA. Side effects of desmopressin in patients with bleeding disorders. Haemophilia. 2016;22(1):39\u201345.","journal-title":"Haemophilia."},{"issue":"5","key":"793_CR47","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/hae.12955","volume":"22","author":"J Windyga","year":"2016","unstructured":"Windyga J, Dolan G, Altisent C, Katsarou O, L\u00f3pez Fern\u00e1ndez MF, Z\u00fclfikar B. Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey. Haemophilia. 2016;22(5):739\u201351.","journal-title":"Haemophilia."},{"key":"793_CR48","first-page":"CD009824","volume":"9","author":"L Karanth","year":"2015","unstructured":"Karanth L, Barua A, Kanagasabai S, Nair NS. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Cochrane Database Syst Rev. 2015;9:CD009824.","journal-title":"Cochrane Database Syst Rev."},{"issue":"2","key":"793_CR49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/14740330902719481","volume":"8","author":"AB Federici","year":"2009","unstructured":"Federici AB. The safety of plasma-derived von Willebrand\/factor VIII concentrates in the management of inherited von Willebrand disease. Expert Opin Drug Saf. 2009;8(2):203\u201310.","journal-title":"Expert Opin Drug Saf."},{"key":"793_CR50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/9781444329926.ch17","volume-title":"Von Willebrand disease","author":"PM Mannucci","year":"2011","unstructured":"Mannucci PM, Franchini M. The use of plasma-derived concentrates. In: Federici AB, Lee CA, Berntorp EE, Lillicrap D, Montgomery RR, editors. Von Willebrand disease. Oxford: Wiley-Blackwell; 2011. p. 200\u20136."},{"issue":"3","key":"793_CR51","first-page":"262","volume":"14","author":"EJ Favaloro","year":"2016","unstructured":"Favaloro EJ. Towards personalised therapy for von Willebrand disease: a future role for recombinant products. Blood Transfusion. 2016;14(3):262\u201376.","journal-title":"Blood Transfusion."},{"issue":"4","key":"793_CR52","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","volume":"167","author":"MA Laffan","year":"2014","unstructured":"Laffan MA, Lester W, O\u2019Donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol. 2014;167(4):453\u201365.","journal-title":"Br J Haematol."},{"issue":"2","key":"793_CR53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0037-1614448","volume":"81","author":"A Lubetsky","year":"1999","unstructured":"Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, et al. Safety and efficacy of continuous infusion of a combined factor VIII\u2014von Willebrand factor (vWF) concentrate (Haemate-P(TM)) in patients with von Willebrand disease. Thromb Haemost. 1999;81(2):229\u201333.","journal-title":"Thromb Haemost."},{"issue":"2","key":"793_CR54","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","volume":"99","author":"PM Mannucci","year":"2002","unstructured":"Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, et al. Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002;99(2):450\u20136.","journal-title":"Blood."},{"issue":"Suppl. 2","key":"793_CR55","first-page":"s33","volume":"6","author":"M Franchini","year":"2008","unstructured":"Franchini M. Surgical prophylaxis in von Willebrand\u2019s disease: a difficult balance to manage. Blood Transfusion. 2008;6(Suppl. 2):s33\u20138.","journal-title":"Blood Transfusion."},{"issue":"3","key":"793_CR56","first-page":"387","volume":"88","author":"M Makris","year":"2002","unstructured":"Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand\u2019s disease. Thromb Haemost. 2002;88(3):387\u20138.","journal-title":"Thromb Haemost."},{"issue":"3","key":"793_CR57","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/j.1365-2516.2012.02758.x","volume":"18","author":"A Coppola","year":"2012","unstructured":"Coppola A, Franchini M, Makris M, Santagostino E, Di Minno G, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia. 2012;18(3):e173\u201387.","journal-title":"Haemophilia."},{"issue":"5","key":"793_CR58","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2516.2011.02583.x","volume":"17","author":"J Paola Di","year":"2011","unstructured":"Di Paola J, Lethagen S, Gill J, Mannucci P, Manco-Johnson M, Bernstein J, et al. Presurgical pharmacokinetic analysis of a von Willebrand factor\/factor VIII (VWF\/FVIII) concentrate in patients with von Willebrand\u2019s disease (VWD) has limited value in dosing for surgery. Haemophilia. 2011;17(5):752\u20138.","journal-title":"Haemophilia."},{"issue":"2","key":"793_CR59","first-page":"117","volume":"7","author":"PO Mannucci","year":"2009","unstructured":"Mannucci PO, Franchini M, Castaman G, Federici AB. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfusion. 2009;7(2):117\u201326.","journal-title":"Blood Transfusion."},{"key":"793_CR60","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Treatment of von Willebrand\u2019s disease. New Engl J Med. 2004;351(7):683-94+730.","DOI":"10.1056\/NEJMra040403"},{"issue":"6","key":"793_CR61","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH10-10-0631","volume":"105","author":"J Windyga","year":"2011","unstructured":"Windyga J, von Depka-Prondzinski M. Efficacy and safety of a new generation von Willebrand factor\/factor VIII concentrate (Wilate\u00ae) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery. Thromb Haemost. 2011;105(6):1072\u20139.","journal-title":"Thromb Haemost."},{"issue":"2","key":"793_CR62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/14740330902719481","volume":"8","author":"AB Federici","year":"2009","unstructured":"Federici AB. The safety of plasma-derived von Willebrand\/factor VIII concentrates in the management of inherited von Willebrand disease. Expert Opin Drug Saf. 2009;8(2):203\u201310.","journal-title":"Expert Opin Drug Saf."},{"issue":"Suppl. 2","key":"793_CR63","first-page":"s9","volume":"9","author":"G Castaman","year":"2011","unstructured":"Castaman G. Treatment of von Willebrand disease with FVIII\/VWF concentrates. Blood Transfusion. 2011;9(Suppl. 2):s9\u201313.","journal-title":"Blood Transfusion."},{"issue":"SUPPL. 5","key":"793_CR64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01847.x","volume":"14","author":"W Schramm","year":"2008","unstructured":"Schramm W. Haemate\u00ae P von Willebrand factor\/factor VIII concentrate: 25 years of clinical experience. Haemophilia. 2008;14(SUPPL. 5):3\u201310.","journal-title":"Haemophilia."},{"issue":"10","key":"793_CR65","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/j.1538-7836.2005.01435.x","volume":"3","author":"J Goudemand","year":"2005","unstructured":"Goudemand J, Scharrer I, Berntorp E, Lee CA, Borel-Derlon A, Stieltjes N, et al. Pharmacokinetic studies on Wilfactin\u00ae, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation\/removal methods. J Thromb Haemost. 2005;3(10):2219\u201327.","journal-title":"J Thromb Haemost."},{"issue":"3","key":"793_CR66","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1365-2516.2008.01679.x","volume":"14","author":"A Iorio","year":"2008","unstructured":"Iorio A, Oliovecchio E, Morfini M, Mannucci PM. Italian registry of haemophilia and allied disorders. Objectives, methodology and data analysis. Haemophilia. 2008;14(3):444\u201353.","journal-title":"Haemophilia."},{"key":"793_CR67","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4613-0331-2_7","volume":"386","author":"PM Mannucci","year":"1995","unstructured":"Mannucci PM, Federici AB. Antibodies to von Willebrand factor in von Willebrand disease. Adv Exp Med Biol. 1995;386:87\u201391.","journal-title":"Adv Exp Med Biol."},{"issue":"5","key":"793_CR68","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1172\/JCI112974","volume":"79","author":"BB Shelton-Inloes","year":"1987","unstructured":"Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest. 1987;79(5):1459\u201365.","journal-title":"J Clin Invest."},{"issue":"1","key":"793_CR69","first-page":"60","volume":"94","author":"ZM Ruggeri","year":"1979","unstructured":"Ruggeri ZM, Ciavarella N, Mannucci PM, Molinari A, Dammacco F, Lavergne JM, et al. Familial incidence of precipitating antibodies in von Willebrand\u2019s disease: a study of four cases. J Lab Clin Med. 1979;94(1):60\u201375.","journal-title":"J Lab Clin Med."},{"issue":"3","key":"793_CR70","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjh.13395","volume":"171","author":"M Baaij","year":"2015","unstructured":"Baaij M, Van Galen KPM, Urbanus RT, Nigten J, Eikenboom JHC, Schutgens REG. First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. Br J Haematol. 2015;171(3):424\u20137.","journal-title":"Br J Haematol."},{"issue":"3","key":"793_CR71","first-page":"348","volume":"125","author":"L Bergamaschini","year":"1995","unstructured":"Bergamaschini L, Mannucci PM, Federici AB, Coppola R, Guzzoni S, Agostoni A. Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor. J Lab Clin Med. 1995;125(3):348\u201355.","journal-title":"J Lab Clin Med."},{"issue":"1","key":"793_CR72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V57.1.25.25","volume":"57","author":"PM Mannucci","year":"1981","unstructured":"Mannucci PM, Ruggeri ZM, Ciavarella N. Precipitating antibodies to factor VIII\/von Willebrand factor in von Willebrand\u2019s disease: effects on replacement therapy. Blood. 1981;57(1):25\u201331.","journal-title":"Blood."},{"key":"793_CR73","first-page":"150","volume":"26","author":"N Ciavarella","year":"1996","unstructured":"Ciavarella N, Schiavoni M, Valenzano E. Use of recombinant factor VIla (NovoSeven\u00ae) in the treatment of two patients with Type III von Willebrand\u2019s Disease and an inhibitor against von Willebrand Factor. Haemostasis. 1996;26:150\u20134.","journal-title":"Haemostasis."},{"issue":"4","key":"793_CR74","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0037-1613878","volume":"83","author":"RE Grossmann","year":"2000","unstructured":"Grossmann RE, Geisen U, Schwender S, Keller F. Continuous infusion of recombinant factor VIIa (NovoSeven\u00ae) in the treatment of a patient with type III von Willebrand\u2019s disease and alloantibodies against von Willebrand factor. Thromb Haemost. 2000;83(4):633\u20134.","journal-title":"Thromb Haemost."},{"issue":"2","key":"793_CR75","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","volume":"109","author":"J Astermark","year":"2007","unstructured":"Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood. 2007;109(2):546\u201351.","journal-title":"Blood."},{"key":"793_CR76","first-page":"197","volume":"18","author":"M Krause","year":"2012","unstructured":"Krause M, K\u00f6nigs C, Pillitteri D, Scholz T, Pilgrimm A, Kirchmaier C, et al. On-demand therapy after ITT failure in patient with von Willebrand disease type 3 and alloantibodies. Haemophilia. 2012;18:197.","journal-title":"Haemophilia."},{"issue":"Suppl 1","key":"793_CR77","first-page":"S32","volume":"29","author":"PL Turecek","year":"2009","unstructured":"Turecek PL, Mitterer A, Matthiessen HP, Gritsch H, Varadi K, Siekmann J, et al. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie. 2009;29(Suppl 1):S32\u20138.","journal-title":"Hamostaseologie."},{"issue":"5","key":"793_CR78","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","volume":"122","author":"PM Mannucci","year":"2013","unstructured":"Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013;122(5):648\u201357.","journal-title":"Blood."},{"issue":"17","key":"793_CR79","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","volume":"126","author":"JC Gill","year":"2015","unstructured":"Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FWG, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126(17):2038\u201346.","journal-title":"Blood."},{"issue":"6","key":"793_CR80","first-page":"427","volume":"38","author":"S Sindet-Pedersen","year":"1991","unstructured":"Sindet-Pedersen S. Haemostasis in oral surgery\u2014the possible pathogenetic implications of oral fibrinolysis on bleeding. Experimental and clinical studies of the haemostatic balance in the oral cavity, with particular reference to patients with acquired and congenital defects of the coagulation system Review. Dan Med Bull. 1991;38(6):427\u201343.","journal-title":"Dan Med Bull."},{"issue":"4","key":"793_CR81","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/0003-4975(96)00022-7","volume":"61","author":"D Katsaros","year":"1996","unstructured":"Katsaros D, Petricevic M, Snow NJ, Woodhall DD, Van Bergen R. Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients. Ann Thorac Surg. 1996;61(4):1131\u20135.","journal-title":"Ann Thorac Surg."},{"issue":"2","key":"793_CR82","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejcts.2008.11.038","volume":"36","author":"AF Later","year":"2009","unstructured":"Later AF, Maas JJ, Engbers FH, Versteegh MI, Bruggemans EF, Dion RA, et al. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial. Eur J Cardiothorac Surg. 2009;36(2):322\u20139.","journal-title":"Eur J Cardiothorac Surg."},{"issue":"6","key":"793_CR83","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1756-0500-6-184","volume":"07","author":"R Gandhi","year":"2013","unstructured":"Gandhi R, Evans HM, Mahomed SR, Mahomed NN. Tranexamic acid and the reduction of blood loss in total knee and hip arthroplasty: a meta-analysis. BMC Res Notes. 2013;07(6):184.","journal-title":"BMC Res Notes."},{"key":"793_CR84","doi-asserted-by":"crossref","unstructured":"van Galen KP, Engelen ET, Mauser-Bunschoten EP, van Es RJ, Schutgens RE. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions. Cochrane Database Syst Rev. 2015;12:CD011385.","DOI":"10.1002\/14651858.CD011385.pub2"},{"issue":"4","key":"793_CR85","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000188524","volume":"69","author":"M Fernandez Lucas","year":"1995","unstructured":"Fernandez Lucas M, Liano F, Navarro JF, Sastre JL, Quereda C, Ortuno J. Acute renal failure secondary to antifibrinolytic therapy. Nephron. 1995;69(4):478\u20139.","journal-title":"Nephron."},{"issue":"3","key":"793_CR86","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/ndt\/14.3.750","volume":"14","author":"JR Koo","year":"1999","unstructured":"Koo JR, Lee YK, Kim YS, Cho WY, Kim HK, Won NH. Acute renal cortical necrosis caused by an antifibrinolytic drug (tranexamic acid). Nephrol Dial Transplant. 1999;14(3):750\u20132.","journal-title":"Nephrol Dial Transplant."},{"issue":"5","key":"793_CR87","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1160\/TH11-03-0180","volume":"106","author":"EM Wee de","year":"2011","unstructured":"de Wee EM, Knol HM, Mauser-Bunschoten EP, van der Bom JG, Eikenboom JCJ, Fijnvandraat K, et al. Gynaecological and obstetric bleeding in moderate and severe von willebrand disease. Thromb Haemost. 2011;106(5):885\u201392.","journal-title":"Thromb Haemost."},{"issue":"3","key":"793_CR88","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/hae.12898","volume":"22","author":"MV Ragni","year":"2016","unstructured":"Ragni MV, Machin N, Malec LM, James AH, Kessler CM, Konkle BA, et al. Von Willebrand factor for menorrhagia: a survey and literature review. Haemophilia. 2016;22(3):397\u2013402.","journal-title":"Haemophilia."},{"issue":"6","key":"793_CR89","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2516.2000.00447.x","volume":"6","author":"PA Kouides","year":"2000","unstructured":"Kouides PA, Phatak PD, Burkart P, Braggins C, Cox C, Bernstein Z, et al. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia. 2000;6(6):643\u20138.","journal-title":"Haemophilia."},{"issue":"1","key":"793_CR90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0010-7824(02)00445-6","volume":"67","author":"M Kwiecien","year":"2003","unstructured":"Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67(1):9\u201313.","journal-title":"Contraception."},{"issue":"4","key":"793_CR91","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0010-7824(91)90028-E","volume":"44","author":"PD Zhu","year":"1991","unstructured":"Zhu PD, Luo HZ, Shi WL, Wang JD, Cheng J, Xu RH, et al. Observation of the activity of factor VIII in the endometrium of women pre- and post-insertion of three types of IUDs. Contraception. 1991;44(4):367\u201384.","journal-title":"Contraception."},{"issue":"12","key":"793_CR92","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1111\/j.1471-0528.2004.00305.x","volume":"111","author":"CEC Kingman","year":"2004","unstructured":"Kingman CEC, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG Int J Obstet Gynaecol. 2004;111(12):1425\u20138.","journal-title":"BJOG Int J Obstet Gynaecol."},{"issue":"13","key":"793_CR93","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2165\/00003495-200363130-00008","volume":"63","author":"K Wellington","year":"2003","unstructured":"Wellington K, Wagstaff AJ. Tranexamic acid\u2014a review of its use in the management of menorrhagia. Drugs. 2003;63(13):1417\u201333.","journal-title":"Drugs."},{"key":"793_CR94","unstructured":"Kadir RA, James AH. Reproductive health in women with bleeding disorders. World Federation of Hemophilia Treatment of Hemophilia Series No 48. 2009. http:\/\/ww.1.wfh.org\/publication\/files\/pdf-1206.pdf . Accessed 30 May 2017."},{"issue":"8","key":"793_CR95","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/emermed-2015-205528","volume":"34","author":"E Bequignon","year":"2017","unstructured":"Bequignon E, Teissier N, Gauthier A, Brugel L, De Kermadec H, Coste A, et al. Emergency Department care of childhood epistaxis. Emerg Med J. 2017;34(8):543\u20138.","journal-title":"Emerg Med J."},{"issue":"2","key":"793_CR96","first-page":"287","volume":"13","author":"N Cocero","year":"2015","unstructured":"Cocero N, Pucci F, Messina M, Pollio B, Mozzati M, Bergamasco L. Autologous plasma rich in growth factors in the prevention of severe bleeding after teeth extractions in patients with bleeding disorders: a controlled comparison with fibrin glue. Blood Transfusion. 2015;13(2):287\u201394.","journal-title":"Blood Transfusion."},{"issue":"4","key":"793_CR97","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2516.2010.02480.x","volume":"17","author":"P Nurden","year":"2011","unstructured":"Nurden P, Youlouz-Marfak I, Siberchicot F, Kostrzewa E, Andia I, Anitua E, et al. Use of autologous platelet-rich clots for the prevention of local injury bleeding in patients with severe inherited mucocutaneous bleeding disorders. Haemophilia. 2011;17(4):620\u20134.","journal-title":"Haemophilia."},{"issue":"5","key":"793_CR98","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MOH.0000000000000167","volume":"22","author":"PA Kouides","year":"2015","unstructured":"Kouides PA. An update on the management of bleeding disorders during pregnancy. Curr Opin Hematol. 2015;22(5):397\u2013405.","journal-title":"Curr Opin Hematol."},{"issue":"2","key":"793_CR99","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2516.2011.02625.x","volume":"18","author":"FY Huq","year":"2012","unstructured":"Huq FY, Kulkarni A, Agbim EC, Riddell A, Tuddenham E, Kadir RA. Changes in the levels of factor VIII and von Willebrand factor in the puerperium. Haemophilia. 2012;18(2):241\u20135.","journal-title":"Haemophilia."},{"issue":"4","key":"793_CR100","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1160\/TH09-10-0704","volume":"103","author":"PB Szecsi","year":"2010","unstructured":"Szecsi PB, Jorgensen M, Klajnbard A, Andersen MR, Colov NP, Stender S. Haemostatic reference intervals in pregnancy. Thromb Haemost. 2010;103(4):718\u201327.","journal-title":"Thromb Haemost."},{"key":"793_CR101","doi-asserted-by":"crossref","unstructured":"James AH, Kouides PA, Abdul-Kadir R, Edlund M, Federici AB, Halimeh S, et al. Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. Am J Obstet Gynecol. 2009;201(1):12.e1\u2013.e8.","DOI":"10.1016\/j.ajog.2009.04.024"},{"issue":"Suppl. 1","key":"793_CR102","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.thromres.2006.01.022","volume":"118","author":"M Makris","year":"2006","unstructured":"Makris M. Gastrointestinal bleeding in von Willebrand disease. Thromb Res. 2006;118(Suppl. 1):S13\u20137.","journal-title":"Thromb Res."},{"issue":"1","key":"793_CR103","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jth.13551","volume":"15","author":"AM Randi","year":"2017","unstructured":"Randi AM, Laffan MA. Von Willebrand factor and angiogenesis: basic and applied issues. J Thromb Haemost. 2017;15(1):13\u201320.","journal-title":"J Thromb Haemost."},{"issue":"3","key":"793_CR104","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1160\/TH13-11-0952","volume":"112","author":"M Franchini","year":"2014","unstructured":"Franchini M, Mannucci PM. Gastrointestinal angiodysplasia and bleeding in von willebrand disease. Thromb Haemost. 2014;112(3):427\u201331.","journal-title":"Thromb Haemost."},{"issue":"4","key":"793_CR105","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2012.04661.x","volume":"10","author":"G Castaman","year":"2012","unstructured":"Castaman G, Federici AB, Tosetto A, La Marca S, Stufano F, Mannucci PM, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost. 2012;10(4):632\u20138.","journal-title":"J Thromb Haemost."},{"issue":"4","key":"793_CR106","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clinre.2016.02.003","volume":"40","author":"A Iannone","year":"2016","unstructured":"Iannone A, Principi M, Barone M, Losurdo G, Ierardi E, Di Leo A. Gastrointestinal bleeding from vascular malformations: Is octreotide effective to rescue difficult-to-treat patients? Clin Res Hepatol Gastroenterol. 2016;40(4):373\u20137.","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"3","key":"793_CR107","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1046\/j.1365-2141.2000.01897.x","volume":"108","author":"M Bowers","year":"2000","unstructured":"Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodysplasia in two patients with von Willebrand\u2019s disease. Br J Haematol. 2000;108(3):524\u20137.","journal-title":"Br J Haematol."},{"issue":"1","key":"793_CR108","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/gut.2004.049031","volume":"54","author":"N Krikis","year":"2005","unstructured":"Krikis N, Tziomalos K, Perifanis V, Vakalopoulou S, Karagiannis A, Garipidou V, et al. Treatment of recurrent gastrointestinal haemorrhage in a patient with von Willebrand\u2019s disease with octreotide LAR and propranolol [7]. Gut. 2005;54(1):171\u20132.","journal-title":"Gut."},{"issue":"9","key":"793_CR109","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91(9):4082\u20135.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"793_CR110","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/hae.12701","volume":"21","author":"ET Engelen","year":"2015","unstructured":"Engelen ET, van Galen KPM, Schutgens REG. Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. Haemophilia. 2015;21(4):419\u201329.","journal-title":"Haemophilia."},{"key":"793_CR111","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.14309\/00000434-201310001-00349","volume":"108","author":"D Kohli","year":"2013","unstructured":"Kohli D, Solomon S, Khatri N, Kessler C, Bull-Henry K. Lenalidomide as a novel therapy for gastrointestinal angiodysplasia. Am J Gastroenterol. 2013;108:S104.","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"793_CR112","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1055\/s-2004-869596","volume":"4","author":"A Skaletz-Rorowski","year":"2004","unstructured":"Skaletz-Rorowski A, Kureishi Y, Shiojima I, Walsh K. The pro- and antiangiogenic effects of statins. Semin Vasc Med. 2004;4(4):395\u2013400.","journal-title":"Semin Vasc Med."},{"issue":"2","key":"793_CR113","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1365-2141.2008.07005.x","volume":"142","author":"M Sohal","year":"2008","unstructured":"Sohal M, Laffan M. Von Willebrand disease and angiodysplasia responding to atorvastatin. Br J Haematol. 2008;142(2):308\u20139.","journal-title":"Br J Haematol."},{"issue":"1","key":"793_CR114","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2009.08031.x","volume":"149","author":"R Alikhan","year":"2010","unstructured":"Alikhan R, Keeling D. Von Willebrand disease, angiodysplasia and atorvastatin. Br J Haematol. 2010;149(1):159\u201360.","journal-title":"Br J Haematol."},{"issue":"3","key":"793_CR115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/hae.12571","volume":"21","author":"M Makris","year":"2015","unstructured":"Makris M, Federici AB, Mannucci PM, Bolton-Maggs PHB, Yee TT, Abshire T, et al. The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease. Haemophilia. 2015;21(3):338\u201342.","journal-title":"Haemophilia."},{"issue":"2","key":"793_CR116","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4193\/Rhino09.201","volume":"49","author":"E Yaniv","year":"2011","unstructured":"Yaniv E, Preis M, Shevro J, Nageris B, Hadar T. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia\u2014a long-term clinical trial. Rhinology. 2011;49(2):214\u20136.","journal-title":"Rhinology."},{"issue":"2","key":"793_CR117","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/lary.20065","volume":"119","author":"E Yaniv","year":"2009","unstructured":"Yaniv E, Preis M, Hadar T, Shvero J, Haddad M. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial. Laryngoscope. 2009;119(2):284\u20138.","journal-title":"Laryngoscope."},{"issue":"1","key":"793_CR118","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000204588","volume":"88","author":"J Mehta","year":"1992","unstructured":"Mehta J, Singhal S, Kamath MV, Mehta BC. A randomized placebo-controlled double-blind study of danazol in hemophilia A. Acta Haematol. 1992;88(1):14\u20136.","journal-title":"Acta Haematol."},{"issue":"1","key":"793_CR119","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood.V65.1.211.211","volume":"65","author":"CK Kasper","year":"1985","unstructured":"Kasper CK, Boylen AL. Poor response to danazol in hemophilia. Blood. 1985;65(1):211\u20133.","journal-title":"Blood."},{"issue":"8","key":"793_CR120","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1097\/MBC.0b013e3283646716","volume":"24","author":"JP Botero","year":"2013","unstructured":"Botero JP, Pruthi RK. Refractory bleeding from intestinal angiodysplasias successfully treated with danazol in three patients with von Willebrand disease. Blood Coagul Fibrinolysis. 2013;24(8):884\u20136.","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"Suppl. 1","key":"793_CR121","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.mbc.0000167659.23262.18","volume":"16","author":"E Berntorp","year":"2005","unstructured":"Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis. 2005;16(Suppl. 1):S23\u20136.","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"3","key":"793_CR122","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2516.2011.02550.x","volume":"17","author":"T Abshire","year":"2011","unstructured":"Abshire T, Bowen J, Berntorp E. Von willebrand disease prophylaxis network. Haemophilia. 2011;17(3):558.","journal-title":"Haemophilia."},{"issue":"9","key":"793_CR123","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.12995","volume":"13","author":"T Abshire","year":"2015","unstructured":"Abshire T, Cox-Gill J, Kempton CL, Leebeek FWG, Carcao M, Kouides P, et al. Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand disease prophylaxis network. J Thromb Haemost. 2015;13(9):1585\u20139.","journal-title":"J Thromb Haemost."},{"issue":"9","key":"793_CR124","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/jth.13036","volume":"13","author":"AB Federici","year":"2015","unstructured":"Federici AB. Prophylaxis in patients with von Willebrand disease: who, when, how? J Thromb Haemost. 2015;13(9):1581\u20134.","journal-title":"J Thromb Haemost."},{"issue":"3","key":"793_CR125","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/j.1365-2516.2011.02745.x","volume":"18","author":"M Franchini","year":"2012","unstructured":"Franchini M, Makris M, Santagostino E, Coppola A, Mannucci PM. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand\u2019s disease: a systematic review of prospective studies. Haemophilia. 2012;18(3):e164\u201372.","journal-title":"Haemophilia."},{"issue":"7","key":"793_CR126","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","volume":"5","author":"S Lethagen","year":"2007","unstructured":"Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, Auerswald G, et al. von Willebrand factor\/factor VIII concentrate (Haemate\u00ae P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost. 2007;5(7):1420\u201330.","journal-title":"J Thromb Haemost."},{"issue":"4","key":"793_CR127","first-page":"533","volume":"11","author":"PO Mannucci","year":"2013","unstructured":"Mannucci PO, Kyrle PA, Schulman S, Di Paola J, Schneppenheim R, Gill JC. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor\/factor VIII concentrate in adults and children with von Willebrand\u2019s disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfusion. 2013;11(4):533\u201340.","journal-title":"Blood Transfusion."},{"issue":"10","key":"793_CR128","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3324\/haematol.2015.136275","volume":"101","author":"H Hazendonk","year":"2016","unstructured":"Hazendonk H, Fijnvandraat K, Lock J, Driessens M, van der Meer F, Meijer K, et al. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica. 2016;101(10):1159\u201369.","journal-title":"Haematologica."},{"issue":"5","key":"793_CR129","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1365-2516.2008.01827.x","volume":"14","author":"MV Ragni","year":"2008","unstructured":"Ragni MV, Jankowitz RC, Chapman HL, Merricks EP, Kloos MT, Dillow AM, et al. A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Haemophilia. 2008;14(5):968\u201377.","journal-title":"Haemophilia."},{"issue":"4","key":"793_CR130","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1160\/TH11-04-0274","volume":"106","author":"MV Ragni","year":"2011","unstructured":"Ragni MV, Jankowitz RC, Jaworski K, Merricks EP, Kloos MT, Nichols TC. Phase II prospective open-label trial of recombinant interleukin-11 in women with mild von Willebrand disease and refractory menorrhagia. Thromb Haemost. 2011;106(4):641\u20135.","journal-title":"Thromb Haemost."},{"issue":"2","key":"793_CR131","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1160\/TH12-06-0447","volume":"109","author":"MV Ragni","year":"2013","unstructured":"Ragni MV, Novelli EM, Murshed A, Merricks EP, Kloos MT, Nichols TC. Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A. Thromb Haemost. 2013;109(2):248\u201354.","journal-title":"Thromb Haemost."},{"issue":"3","key":"793_CR132","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1160\/TH10-01-0027","volume":"104","author":"B Jilma","year":"2010","unstructured":"Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Kn\u00f6bl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost. 2010;104(3):563\u201370.","journal-title":"Thromb Haemost."},{"issue":"2","key":"793_CR133","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1160\/TH11-12-0889","volume":"108","author":"P Jilma-Stohlawetz","year":"2012","unstructured":"Jilma-Stohlawetz P, Kn\u00f6bl P, Gilbert JC, Jilma B. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease. Thromb Haemost. 2012;108(2):284\u201390.","journal-title":"Thromb Haemost."},{"issue":"1\u20132","key":"793_CR134","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejps.2012.10.014","volume":"48","author":"P Sundaram","year":"2013","unstructured":"Sundaram P, Kurniawan H, Byrne ME, Wower J. Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci. 2013;48(1\u20132):259\u201371.","journal-title":"Eur J Pharm Sci."},{"issue":"25","key":"793_CR135","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357\u201365.","journal-title":"N Engl J Med."},{"issue":"21","key":"793_CR136","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994\u20132004.","journal-title":"N Engl J Med."},{"issue":"9","key":"793_CR137","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1161\/ATVBAHA.108.168369","volume":"28","author":"SF Meyer De","year":"2008","unstructured":"De Meyer SF, Vandeputte N, Pareyn I, Petrus I, Lenting PJ, Chuah MKL, et al. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol. 2008;28(9):1621\u20136.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"6","key":"793_CR138","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1089\/hum.2011.238","volume":"23","author":"L Wang","year":"2012","unstructured":"Wang L, Rosenberg JB, De BP, Ferris B, Wang R, Rivella S, et al. In vivo gene transfer strategies to achieve partial correction of von Willebrand disease. Hum Gene Ther. 2012;23(6):576\u201388.","journal-title":"Hum Gene Ther."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0793-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0793-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T02:01:24Z","timestamp":1719367284000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0793-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,8]]},"references-count":138,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0793-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,8]]}}}